Testing an infection model to explain excess risk of preterm birth with long-term iron supplementation in a malaria endemic area.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
26 Nov 2019
Historique:
received: 23 09 2019
accepted: 16 11 2019
entrez: 28 11 2019
pubmed: 28 11 2019
medline: 24 3 2020
Statut: epublish

Résumé

In view of recent evidence from a randomized trial in Burkina Faso that periconceptional iron supplementation substantially increases risk of spontaneous preterm birth (< 37 weeks) in first pregnancies (adjusted relative risk = 2.22; 95% CI 1.39-3.61), explanation is required to understand potential mechanisms, including progesterone mediated responses, linking long-term iron supplementation, malaria and gestational age. The analysis developed a model based on a dual hit inflammatory mechanism arising from simultaneous malaria and gut infections, supported in part by published trial results. This model is developed to understand mechanisms linking iron supplementation, malaria and gestational age. Background literature substantiates synergistic inflammatory effects of these infections where trial data is unavailable. A path modelling exercise assessed direct and indirect paths influencing preterm birth and gestation length. A dual hit hypothesis incorporates two main pathways for pro-inflammatory mechanisms, which in this model, interact to increase hepcidin expression. Trial data showed preterm birth was positively associated with C-reactive protein (P = 0.0038) an inflammatory biomarker. The malaria pathway upregulates C-reactive protein and serum hepcidin, thereby reducing iron absorption. The enteric pathway results from unabsorbed gut iron, which induces microbiome changes and pathogenic gut infections, initiating pro-inflammatory events with lipopolysaccharide expression. Data from the trial suggest that raised hepcidin concentration is a mediating catalyst, being inversely associated with shorter gestational age at delivery (P = 0.002) and positively with preterm incidence (P = 0.007). A segmented regression model identified a change-point consisting of two segments before and after a sharp rise in hepcidin concentration. This showed a post change hepcidin elevation in women with increasing C-reactive protein values in late gestation (post-change slope 0.55. 95% CI 0.39-0.92, P < 0.001). Path modelling confirmed seasonal malaria effects on preterm birth, with mediation through C-reactive protein and (non-linear) hepcidin induction. Following long-term iron supplementation, dual inflammatory pathways that mediate hepcidin expression and culminate in progesterone withdrawal may account for the reduction in gestational age observed in first pregnancies in this area of high malaria exposure. If correct, this model strongly suggests that in such areas, effective infection control is required prior to iron supplementation to avoid increasing preterm births. Trial registration NCT01210040. Registered with Clinicaltrials.gov on 27th September 2010.

Sections du résumé

BACKGROUND BACKGROUND
In view of recent evidence from a randomized trial in Burkina Faso that periconceptional iron supplementation substantially increases risk of spontaneous preterm birth (< 37 weeks) in first pregnancies (adjusted relative risk = 2.22; 95% CI 1.39-3.61), explanation is required to understand potential mechanisms, including progesterone mediated responses, linking long-term iron supplementation, malaria and gestational age.
METHODS METHODS
The analysis developed a model based on a dual hit inflammatory mechanism arising from simultaneous malaria and gut infections, supported in part by published trial results. This model is developed to understand mechanisms linking iron supplementation, malaria and gestational age. Background literature substantiates synergistic inflammatory effects of these infections where trial data is unavailable. A path modelling exercise assessed direct and indirect paths influencing preterm birth and gestation length.
RESULTS RESULTS
A dual hit hypothesis incorporates two main pathways for pro-inflammatory mechanisms, which in this model, interact to increase hepcidin expression. Trial data showed preterm birth was positively associated with C-reactive protein (P = 0.0038) an inflammatory biomarker. The malaria pathway upregulates C-reactive protein and serum hepcidin, thereby reducing iron absorption. The enteric pathway results from unabsorbed gut iron, which induces microbiome changes and pathogenic gut infections, initiating pro-inflammatory events with lipopolysaccharide expression. Data from the trial suggest that raised hepcidin concentration is a mediating catalyst, being inversely associated with shorter gestational age at delivery (P = 0.002) and positively with preterm incidence (P = 0.007). A segmented regression model identified a change-point consisting of two segments before and after a sharp rise in hepcidin concentration. This showed a post change hepcidin elevation in women with increasing C-reactive protein values in late gestation (post-change slope 0.55. 95% CI 0.39-0.92, P < 0.001). Path modelling confirmed seasonal malaria effects on preterm birth, with mediation through C-reactive protein and (non-linear) hepcidin induction.
CONCLUSIONS CONCLUSIONS
Following long-term iron supplementation, dual inflammatory pathways that mediate hepcidin expression and culminate in progesterone withdrawal may account for the reduction in gestational age observed in first pregnancies in this area of high malaria exposure. If correct, this model strongly suggests that in such areas, effective infection control is required prior to iron supplementation to avoid increasing preterm births. Trial registration NCT01210040. Registered with Clinicaltrials.gov on 27th September 2010.

Identifiants

pubmed: 31771607
doi: 10.1186/s12936-019-3013-6
pii: 10.1186/s12936-019-3013-6
pmc: PMC6880560
doi:

Substances chimiques

Iron E1UOL152H7

Banques de données

ClinicalTrials.gov
['NCT01210040']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

374

Subventions

Organisme : NIH HHS
ID : U01HD061234-01A1
Pays : United States

Références

Sci Rep. 2015 Oct 05;5:14603
pubmed: 26434367
Trans R Soc Trop Med Hyg. 1989 Mar-Apr;83(2):173-7
pubmed: 2692225
BMC Med. 2016 Jun 13;14(1):86
pubmed: 27291689
PLoS Pathog. 2014 Jan;10(1):e1003885
pubmed: 24453977
PLoS One. 2013;8(2):e56161
pubmed: 23409146
Vitam Horm. 2019;110:143-156
pubmed: 30798809
Horm Behav. 2017 Feb;88:45-51
pubmed: 27816626
Semin Perinatol. 2017 Nov;41(7):420-426
pubmed: 28889957
J Infect Dis. 2017 Dec 19;216(12):1601-1610
pubmed: 29029247
Malar J. 2014 Jul 11;13:271
pubmed: 25015559
Hum Reprod. 2005 Nov;20(11):3235-7
pubmed: 16037105
Immunol Rev. 2017 May;277(1):61-75
pubmed: 28462526
BMC Med. 2017 Nov 23;15(1):206
pubmed: 29166928
J Inflamm Res. 2012;5:67-75
pubmed: 22924006
Microorganisms. 2016 Jun 15;4(2):null
pubmed: 27681914
Curr Opin Obstet Gynecol. 2015 Apr;27(2):133-42
pubmed: 25692506
Mol Biochem Parasitol. 2013 Mar;188(1):63-77
pubmed: 23500968
Am J Trop Med Hyg. 2018 Feb;98(2):520-523
pubmed: 29313480
Clin Infect Dis. 2014 Mar;58(5):638-47
pubmed: 24336909
Malar J. 2017 Oct 5;16(1):400
pubmed: 28982374
Curr Opin Gastroenterol. 2011 Oct;27(6):523-8
pubmed: 21785351
Math Biosci. 2014 Dec;258:19-32
pubmed: 25245609
Psychoneuroendocrinology. 2018 Aug;94:49-62
pubmed: 29754005
Placenta. 2015 Jun;36(6):674-80
pubmed: 25819809
Eur J Clin Nutr. 2019 Nov;73(11):1464-1472
pubmed: 31168085
Malar J. 2019 May 6;18(1):161
pubmed: 31060615
Microbes Infect. 2005 Aug-Sep;7(11-12):1217-23
pubmed: 16002311
PLoS One. 2011;6(12):e28540
pubmed: 22174834
J Leukoc Biol. 2019 Apr;105(4):645-655
pubmed: 30570786
Lancet Glob Health. 2019 Jan;7(1):e37-e46
pubmed: 30389451
Cell Rep. 2014 Jan 16;6(1):196-210
pubmed: 24388751
J Trace Elem Med Biol. 2018 May;47:12-20
pubmed: 29544798
JAMA. 2015 Sep 8;314(10):1009-20
pubmed: 26348751
Trends Parasitol. 2014 Feb;30(2):85-94
pubmed: 24388420
Scand J Immunol. 2014 May;79(5):299-304
pubmed: 24498969
Semin Fetal Neonatal Med. 2016 Apr;21(2):74-9
pubmed: 26740166
Am J Clin Nutr. 2015 Dec;102(6):1450-9
pubmed: 26561613
Trials. 2016 Jan 30;17:58
pubmed: 26833080
Environ Health. 2019 Jan 3;18(1):1
pubmed: 30606207
Sci Rep. 2019 Feb 19;9(1):2260
pubmed: 30783215
Clin Infect Dis. 2015 May 15;60(10):1481-8
pubmed: 25694651
J Infect Dis. 2018 Aug 24;218(7):1099-1109
pubmed: 29733403
Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S23-31
pubmed: 26933016
J Ren Nutr. 2018 Jan;28(1):1-3
pubmed: 29249294
J Immunol. 2015 Apr 1;194(7):3275-85
pubmed: 25725110
Infect Immun. 2004 Dec;72(12):7022-9
pubmed: 15557625
Clin Nutr. 2019 Jan 26;:
pubmed: 30737046
Reprod Biol Endocrinol. 2015 Oct 07;13:115
pubmed: 26446923
Immunohorizons. 2017 Jun 1;1(4):29-41
pubmed: 28890952
Am J Clin Nutr. 2017 Dec;106(Suppl 6):1567S-1574S
pubmed: 29070542
Metallomics. 2017 Feb 22;9(2):101-111
pubmed: 28067386
J Obstet Gynaecol Res. 2007 Oct;33(5):710-7
pubmed: 17845335
Front Immunol. 2015 Apr 20;6:166
pubmed: 25941525
Mol Immunol. 2018 May;97:82-93
pubmed: 29602073
J Clin Invest. 2016 Jan;126(1):389-401
pubmed: 26657863
Am J Clin Nutr. 2010 Dec;92(6):1385-92
pubmed: 20926522
Am J Reprod Immunol. 2004 Aug;52(2):174-83
pubmed: 15274659
Am J Reprod Immunol. 2014 Jan;71(1):61-72
pubmed: 24128422
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):9-21
pubmed: 27848962
Am J Reprod Immunol. 2011 Feb;65(2):110-7
pubmed: 20712808
BJOG. 2009 Oct;116(11):1515-9
pubmed: 19614937
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
Nat Rev Immunol. 2018 Apr;18(4):266-278
pubmed: 29332936
Placenta. 2015 Apr;36(4):341-4
pubmed: 25637411
Trends Endocrinol Metab. 2012 Oct;23(10):516-23
pubmed: 22682480
BMJ. 2018 Jan 8;360:j5145
pubmed: 29311119
Nat Med. 2011 Jun;17(6):732-7
pubmed: 21572427
Placenta. 2004 May;25(5):359-78
pubmed: 15081631
Infect Immun. 2018 Aug 22;86(9):
pubmed: 29986892
PLoS One. 2014 Mar 03;9(3):e90128
pubmed: 24595186
Am J Reprod Immunol. 2014 Nov;72(5):458-74
pubmed: 25078709
BMC Public Health. 2019 Feb 28;19(1):249
pubmed: 30819132
Eur J Pharmacol. 2015 Dec 15;769:110-6
pubmed: 26548622
Biochem Mol Biol J. 2016;2(2):
pubmed: 27790644
Nutr Rev. 2013 Aug;71(8):528-40
pubmed: 23865798
Cell. 2017 Nov 2;171(4):783-794.e13
pubmed: 28942917
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
J Pediatr Surg. 2016 Jan;51(1):13-7
pubmed: 26577908
Biol Reprod. 2019 May 1;100(5):1290-1305
pubmed: 30590393
Am J Trop Med Hyg. 2018 Feb;98(2):534-542
pubmed: 29210351
Curr Opin Microbiol. 2017 Dec;40:131-137
pubmed: 29175338
Front Pharmacol. 2014 May 30;5:125
pubmed: 24910614
BMC Med. 2018 Sep 20;16(1):156
pubmed: 30231938
Malar J. 2016 Feb 01;15:54
pubmed: 26830671
Fetal Pediatr Pathol. 2015;34(6):407-12
pubmed: 26503894
PLoS One. 2015 Aug 12;10(8):e0134633
pubmed: 26267795
J Reprod Immunol. 2017 Feb;119:62-66
pubmed: 28122664
Biomark Res. 2017 Dec 13;5:34
pubmed: 29255607
Gynecol Endocrinol. 2015 Apr;31(4):309-12
pubmed: 25539190
Peptides. 2006 Jun;27(6):1457-63
pubmed: 16309788
Biochim Biophys Acta. 2012 Sep;1823(9):1434-43
pubmed: 22306005
ISME J. 2018 Jun;12(7):1631-1641
pubmed: 29434315
FEMS Microbiol Rev. 2016 Jul;40(4):480-93
pubmed: 27075488
Clin Infect Dis. 2017 Oct 30;65(10):1729-1735
pubmed: 29020221
Endocrinology. 2017 Jan 1;158(1):158-169
pubmed: 27886516

Auteurs

Bernard Brabin (B)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L35QA, UK. b.j.brabin@liverpool.ac.uk.
Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. b.j.brabin@liverpool.ac.uk.
Global Child Health Group, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. b.j.brabin@liverpool.ac.uk.

Halidou Tinto (H)

Clinical Research Unit of Nanoro (URCN/IRSS), Nanoro, Burkina Faso.

Stephen A Roberts (SA)

Centre for Biostatistics, Division of Population Health, Health Services Research and Primary Care, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH